> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Vaccines Panel Mulls Omicron Boosters
- URL: https://www.fdaweb.com/vaccines-panel-mulls-omicron-boosters/
- Published: 2022-06-27T12:00:00.000Z
- Updated: 2026-09-14T17:50:10.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5152172

FDA’s Vaccines and Related Biological Products Advisory Committee is meeting 6/28 to discuss whether and how the SARS-CoV-2 strain composition of Covid-19 vaccine boosters should be modified for use this fall and winter. This is a follow-up meeting to a 4/6 panel deliberation that discussed how the primary Covid-19 vaccinations and booster shots have decreased effectiveness against the Omicron variants and waning effectiveness over time. Some health experts predict another late-year Covid infection wave as people remain indoors again during the colder months, and the agency has said a decision must be made this summer for the vaccines to be available in November.

Both Pfizer-BioNTech and Moderna have studied newer vaccines that are based on the current Omicron variant that the panel members will be reviewing. “The current epidemiology of SARS-CoV-2, the evidence of waning immunity elicited by current Covid-19 vaccines, and the available immunogenicity data generated from a limited number of variant-specific vaccine candidates suggest that an updated vaccine composition may provide added benefit against currently circulating virus variants,” a just-released FDA [briefing document](https://www.fda.gov/media/159452/download?ref=fdaweb.com) says.

FDA says the only voting question panel members have is: “Does the committee recommend inclusion of a SARS-CoV-2 Omicron component for Covid-19 booster vaccines in the U.S.?”